Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.
IPO Year: 2022
Exchange: NASDAQ
Website: https://viraxbiolabs.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/31/2025 | $3.00 | Buy | H.C. Wainwright |
SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)
SC 13G - Virax Biolabs Group Ltd (0001885827) (Subject)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
S-8 - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
LONDON, Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO"). Dr. McCracken will succeed Mr. Cameron Shaw, who is moving to Virax's Advisory Board, and will lead the Company's various growth initiatives, including the Company's expected near-term research-use-only launch of ViraxImmune™. "We are excited to welcome Dr.
LONDON, Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales. "We are thrilled to welcome Richard to our team," said James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs. "Richard brings almost 25 years of experience in successfully commercializing novel and disruptive technological products in the research, routine
H.C. Wainwright initiated coverage of Virax Biolabs Group Ltd. with a rating of Buy and set a new price target of $3.00
LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179). Conducted in collaboration with the United Kingdom's National Health Service, investigators aim to assess the ViraxImmune™ FluoroSpot T cell assay performance in detecting T cell dysfunction in post-acute infection syndrome patient
LONDON, March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role of T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. PAISs are often associated with a dysfunction of the immune system, notably progressive T-Cell exhaustion. Chronic antigen stimulation following a chronic infection can
LONDON, March 5, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present at the 19th World Immune Regulation Meeting (WIRM), which will take place March 12-15, 2025, in Davos, Switzerland. Presentation Details: Title: Evaluation of T cell dysfunction in post acute infection syndromesPresenter: Dr. Nigel McCracken, Chief Operating Officer at Virax BiolabsDate: Wednesday, Ma
Company Positioned to Support Public Health through Vaccine Efficacy Testing and Data-Driven Insights into Patients' Immune Profiles to Empower Informed Decisions on Vaccination LONDON, Feb. 25, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") believes that its technology aligns with the United States Department of Health and Human Services' commitment to prioritizing transparency on vaccine efficacy. This initiative is essential for empowering the public with the information needed to make informed health decisions. Virax Biolabs recog
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus ("AIV") Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council (GCC) countries.Specifically, Cosmos Health gains exclusive rights t
LONDON, Dec. 17, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders outlining the Company's plans for 2025 and highlights recent accomplishments. Dear Fellow Shareholders, As we wrap up 2024 and look forward to the year ahead, we are excited to share an update on our achievements and outline our strategic goals for
LONDON, Dec. 10, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland. "We are honored to announce this agreement with Tebubio, who will prove to be instrumental in increasing th
LONDON, Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience. "ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to par
CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an extension of its existing exclusive distribution agreement with Virax Biolabs (NASDAQ:VRAX) to commercialize mpox virus real-time PCR detection kits in countries within the Gulf Cooperation Council ("GCC"). It had previously signed an agreement for exclusive distribution in Greece and Cyprus, as
LONDON, Sept. 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into an extension of its already existing exclusive distribution agreement with Cosmos Health Inc. (NASDAQ:COSM) ("Cosmos") to commercialize Mpox Virus Real-Time PCR Detection Kits in countries in the Gulf Cooperation Council ("GCC"). It had previously signed an agreement for exclusive distribution in Greece & Cyrprus and non-exclusive distribution throughout Europe.